MBX Logos FINAL FULL.jpg
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
October 05, 2022 09:00 ET | MBX Biosciences, Inc.
CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Logos FINAL FULL.jpg
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
July 26, 2022 12:00 ET | MBX Biosciences, Inc.
CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders,...
MBX Logos FINAL FULL.jpg
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
April 11, 2022 07:30 ET | MBX Biosciences, Inc.
CARMEL, Ind., April 11, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine...
MBX Logos FINAL FULL.jpg
MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
April 05, 2022 08:00 ET | MBX Biosciences, Inc.
CARMEL, Ind., April 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine...